Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxoprubart Phase 1 SAD in Healthy Subjects
NCT05642546Phase 1Completed
- Sponsor
- NovelMed Therapeutics
- Start
- Aug 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing NM8074 with Placebo (2 arms). Primary endpoint: Monitoring of Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Aug 2020; status: completed.
02
Drugs
ruxoprubart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05642546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642546.